logo-horizontal-main.png
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
08 oct. 2024 08h30 HE | OncoCyte Corporation
Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO...
logo-horizontal-main.png
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
30 mai 2024 16h47 HE | OncoCyte Corporation
Late-breaking presentation of data at American Transplant Congress on Monday, June 3Data show potential to monitor for therapeutic efficacy and recurrencePotential repeat testing opportunities with...